Tasimelteon, an experimental drug created to treat a rare sleep disorder called non-24-hour sleep-wake disorder (non-24), passed its second late-stage trial. The results were reported as being surprisingly good.
Non-24 is a rare, cicardian rhythm sleep disorder. It causes hourly delays in sleep onset and wake times.
Powered by Facebook Comments